Herceptin Products (Trastuzumab)
Customize your policy alerts
Sign up for all Mass General Brigham Health Plan policy alerts
Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization for trastuzumab reference, biosimilar, and subcutaneous products provided under the medical benefit for MassHealth members. It establishes coverage criteria for HER2-overexpressing breast cancer, HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, and RAS wild-type HER2-positive unresectable or metastatic colorectal cancer.
Hercessi (trastuzumab-strf) was added as a covered trastuzumab product in the policy criteria.
Kanjinti (trastuzumab-anns) was added as the step-through preferred product for other trastuzumab products.
The clinical rationale requirement for non-preferred trastuzumab products was clarified.
The policy was reformatted and its references were updated.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.